Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that as of March 31, 2009, the Company had been served or was aware that it had been named…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that on April 6, 2009, the Company filed a supplemental brief in the product liability suit McDarby v. Merck.
The…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that during 2009, the Company anticipates that it will make total payments of US$3.4 billion into the Vioxx settlement…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that 15 of the 18 separate lawsuits brought by government entities have been transferred to the federal MDL and…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that the plaintiffs in the case Garza v. Merck filed their response on a petition for review on Feb.…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that it is pursuing all appropriate remedies to avoid having the penalty assessed by the Canada Revenue Agency.
Merck’s Canadian…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that the plaintiffs in a suit filed against BrownGreer, the claims administrator for the company’s Settlement Program (the “Claims…
Merck & Co., Inc. is working with Schering-Plough Corporation to respond to the investigations conducted by various government agencies related to the ENHANCE clinical trial and the Zetia and Vytorin sales.
ENHANCE is an imaging trial conducted by the MSP Partnership…
Merck & Co., Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that it is pursuing all appropriate remedies to avoid having the penalty assessed by the Canada Revenue Agency.
Merck’s Canadian…
Merck & Co., Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that it continues to have disputes with the insurers about the availability of some or all of the insurance…